Characterization of CD8(+) T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)

Ítems similars

• Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with Ipilimumab in patients with pretreated advanced melanoma
  per: Thielemans, Kris, et al.
  Publicat: (2014)
• Clinical trials with MRNA electroporated dendritic cells for stage III/IV melanoma patients
  per: Wilgenhof, Sofie, et al.
  Publicat: (2015)
• Overcoming HLA restriction in clinical trials: Immune monitoring of mRNA-loaded DC therapy
  per: Van Nuffel, An M.T., et al.
  Publicat: (2012)
• Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4(+) and CD8(+) T Cells in Melanoma Patients
  per: Van Nuffel, An MT, et al.
  Publicat: (2012)
• TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
  per: De Keersmaecker, Brenda, et al.
  Publicat: (2020)